Mesa Laboratories(NASDAQ:MLAB) announced the earnings results for Fiscal Year 2017 and Q1. The results came in during Pre-market on Jul 28, 2016. Company reported revenue of $21.11M. Analysts estimated a revenue of $21.48M. Earnings per share were $0.89. Analysts had estimated an EPS of $0.93.
In a different note, On Jun 10, 2016, Sidoti & Co. said it Downgrades its rating on Mesa Laboratories. The shares have been rated ‘Neutral’ by the firm.
Mesa Laboratories (MLAB) shares turned negative on Thursdays trading session with the shares closing down -1.76 points or -1.67% at a volume of 23,326. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $107.59. The peak price level was also seen at $107.59 while the days lowest was $102.85. Finally the shares closed at $103.37. The 52-week high of the shares is $131.88 while the 52-week low is $77. According to the latest information available, the market cap of the company is $376 M.
Mesa Laboratories has also declared a cash dividend of $0.1600 on Jul 6, 2016. The shares will quote ex-dividend on Aug 29, 2016 and the record date has been fixed on Aug 31, 2016. The dividend payable date has been fixed on Sep 15, 2016.
Several Insider Transactions has been reported to the SEC. On Jun 23, 2016, John James Sullivan (President and CEO) sold 4,000 shares at $121.63 per share price.Also, On Jun 8, 2016, Glenn E Adriance (CSMO) sold 3,000 shares at $111.74 per share price.On Mar 9, 2016, H Stuart Campbell (director) sold 280 shares at $90.00 per share price, according to the Form-4 filing with the securities and exchange commission.
Mesa Laboratories Inc. is primarily focused on quality control products. The Company has three segments: Instruments Biological Indicators and Continuous Monitoring. The Company’s Instruments segment designs manufactures and markets quality control instruments and disposable products utilized in connection with the healthcare pharmaceutical food and beverage medical device industrial hygiene environmental air sampling and semiconductor industries. Its Biological Indicators segment manufactures and markets biological indicators and distributes chemical indicators used to assess the effectiveness of sterilization processes in the hospital dental medical device and pharmaceutical industries. Its Continuous Monitoring segment designs develops and markets systems which are used to monitor various environmental parameters in hospitals pharmaceutical and medical device manufacturers blood banks pharmacies and a number of other laboratory and industrial environments.